GE Hitachi Nuclear Energy (GEH) announced today it has been selected by
the U.S. Department of Energy’s National Nuclear Security Administration
(NNSA) to help develop a U.S. supply of a radioisotope used in more than
20 million diagnostic medical procedures in the United States each year.
“We are seeking some short-term solutions that have long-term potential,
and the GEH technical solution provides a path forward that is quite
attractive to meet both these needs”
NNSA has chosen GEH to help create a reliable U.S. supply of
molybdenum-99 without the use of highly enriched uranium (HEU) to
respond to a shortage from repeated, unplanned outages at facilities
where it currently is produced.
Molybdenum-99 is the precursor of technetium-99m, the radioisotope most
widely used in nuclear medicine diagnostic procedures, including the
detection of cancer, heart disease and thyroid disease, along with the
study of brain and kidney function and the imaging of stress fractures,
according to the Society of Nuclear Medicine.
GEH’s new technology does not rely on the fissioning of HEU, advancing a
key non-proliferation initiative for the United States. Because GEH’s
technology can be used in existing nuclear reactors, the need to build
new reactors dedicated to isotope production is reduced.
“NNSA is committed to supporting technology that offers a new path
forward for the creation of a reliable, domestic supply of molybdenum-99
without the use of HEU,” said NNSA Administrator Thomas D'Agostino.
“This pragmatic approach addresses a critical U.S. medical community
need while supporting President Obama's goal of reducing the risk posed
by global use of HEU.”
Deploying GEH’s isotope production technology potentially could meet at
least 50 percent of the United States’ projected supply needs for
molybdenum-99/technetium-99m to help ensure patient access to vital
medical diagnostic procedures. GEH will conduct research and development
to confirm its technology at commercial scale and determine the
infrastructure and logistics needed to support commercial operation.
“We are seeking some short-term solutions that have long-term potential,
and the GEH technical solution provides a path forward that is quite
attractive to meet both these needs,” said Robert Atcher, M.D., PhD.,
past president of the Society of Nuclear Medicine, who evaluated GEH’s
isotope technology.